Regenerative medicine: Does erythropoietin have a role?

Current Pharmaceutical Design

Volumn 15, Issue 17, 2009, Pages 2026-2036

  Buemi, Michele ^a,c   Lacquaniti, Antonio ^a   Maricchiolo, Giulia ^b   Bolignano, Davide ^a   Campo, Susanna ^a   Cernaro, Valeria ^a   Sturiale, Alessio ^a   Grasso, Giovanni ^a   Buemi, Antoine ^a   Allegra, Alessandro ^a   Donato, Valentina ^a   Genovese, Lucrezia ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR   (Italy)

^c NONE   (Italy)

Author keywords

Angiogenesis; Erythropoietin; Regenerative medicine

Indexed keywords

ASIALOERYTHROPOIETIN; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CELL PROLIFERATION; DIABETIC RETINOPATHY; ENDOTHELIAL STEM CELL; ERYTHROPOIESIS; GENE EXPRESSION; HEART INFARCTION; HORMONE ACTION; HUMAN; HYPOXIA; LIVER CELL; LIVER SINUSOID; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANIMALS; ERYTHROPOIETIN; FISHES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; REGENERATIVE MEDICINE;

EID: 68449085754     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788453194     Document Type: Review

References (72)

1. DeWitt N. Regenerative medicine. Nature 2008; 453(7193): 301
2. Brockes JP. Mitogenic growth factor and nerve dependence of limb regeneration. Science 1984; 225: 1280-7.
3. Brockes JP, Kumar A. Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science 2005; 310: 1919-23
4. Stocum DL Amphibian regeneration and stem cells. Curr Top Microbiol Immuniol 2004; 280: 1-70.
5. Stoick-Cooper CL, Moon RT, Weidinger G. Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes Dev 2007; 21(11): 1292-315.
6. Sperschneider H, Neumann K, Ruffert K, Stein G. Influence of recombinant human erythropoietin therapy on in vivo chemotaxis and in vitro phagocytosis of polymorphonuclear cells of hemodialysis patients. Blood Purif 1996; 14(2): 157-64
7. Buemi M, Nostro L, Romeo A, Giacobbe MS, Aloisi C, Sturiale A, et al. From the oxygen to the organ protection: Erythropoietin as protagonist in internal medicine. Cardiovasc Hematol Agents Med Chem 2006; 4(4): 299-311.
8. Semenza GL. O2 sensing: Only skin deep? Cell 2008; 133(2): 223-34.
9. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 2007(407): Cm8.
10. Allegra A, Buemi M, Corica F, Giacobbe MS, Frisina N, Ceruso D. Erythropoietin: Current aspects and prospects. Recenti Prog Med 1989; 80(10): 531-6.
11. Yamaji R, Okada T, Moriya M, Naito M, Tsurio T, Miyatake K, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239(2): 494-500.
12. Marti HH, Gassmann M, Wenger RH, et al. Detection of erythropoietin in human liquor: Intrinsic erythropoietin production in the brain. Kidney Int 1997; 51(2): 416-8.
13. Choi K. Hemangioblast development and regulation. Biochem Cell Biol 1998; 76(6): 947-56.
14. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, Vol. 93 No. 8 (April 15), 1999: Pp. 2627-36.
15. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003; 62(3): 228-36.
16. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008.
17. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci USA 2008; 105(16): 6185-90.
18. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem 2004; 279(20): 20655-62.
19. Aydin Z, Duijs J, Bajema IM, van Zonneveld AJ, Rabelink TJ. Erythropoietin, progenitors, and repair. Kidney Int Suppl 2007; (107): S16-20.
20. Schmidt RE, Green KG, Feng D, Dorsey DA, Parvin CA, Lee JM, et al. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 2008; 209(1): 161-70.
21. Madeddu P, Emanueli C. Switching on reparative angiogenesis: Essential role of the vascular erythropoietin receptor. Circ Res 2007; 100(5): 662-9.
22. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9(6): 653-60.
23. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003; 33(10): 891-6.
24. Caccamo C, Nostro L, Giorgianni G, Mondello S, Crascì E, Frisina N, et al. Behavior of vascular endothelial growth factor and erythropoietin throughout the menstrual cycle in healthy women. J Reprod Med 2007; 52(11): 1035-9.
25. Buemi M, Vaccaro M, Sturiale A, Galeano MR, Sansotta C, Cavallari V, et al. Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps. Acta Derm Venereol 2002; 82(6): 411-7.
26. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. PNAS, 2004.
27. U.S. Food and Drug Administration, http://www.fda.gov/cder/drug/ infopage/RHE/default.htm, Accessed May 12, 2007.
28. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial, Mol. Med 2002; 8: 495-505.
29. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006; 48: 2161-7.
30. Boogaerts M, Pleiotropic effects of erythropoietin in neuronal and vascular systems, Curr Med Res Opin 2006; 22(Suppl. 4): 15-22.
31. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alpha in patients with acute myocardial infarction: a randomized feasibility and safety study, Cardiovasc. Drugs Ther 2006; 20: 135-41.
32. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Rationale-trial to reduce cardiovascular events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 2005; 149: 408-13.
33. Efthimiadou A, Pagonopoulou O, Lambropoulou M, Papadopoulos N, Nikolettos NK. Erythropoietin enhances angiogenesis in an experimental cyclosporine a-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 2007; 34(9): 866-9.
34. Jaquet K. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64(2): 326-33.
35. Broberg AM, Grinnemo KH, Genead R, Danielsson C, Andersson AB, Wärdell E, et al. Erythropoietin has an antiapoptotic effect after myocardial infarction and stimulates in vitro aortic ring sprouting. Biochem Biophys Res Commun 2008; 371(1): 75-8.
36. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12(7): 732-4.
37. Sturiale A, Campo S, Crascì E, Aloisi C, Buemi M. Experimental models of acute renal failure and erythropoietin: What evidence of a direct effect? Ren Fail 2007; 29(3): 379-86.
38. Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, Jiang A, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J Cereb Blood Flow Metab 2008
39. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Yang N, et al. First affiliated hospital of Nanjing Medical university, Nanjing, China. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl Int 2007; 20(2): 174-83.
40. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007; 115(15): 2022-32.
41. Chu CY, Cheng CH, Chen GD, Chen YC, Hung CC, Huang KY, et al. The zebrafish erythropoietin: Functional identification and biochemical characterization. FEBS Letters 2007; 581: 4265-71.
42. Wickramasinghe SN. Erythropoietin and the human kidney: Evidence for an evolutionary link from studies of Salmo gairdneri. Comp Biochem Physiol Comp Physiol 1993; 104(1): 63-5.
43. Jimmy C, Lai C, Kakuta I, Helen O, Mok L, Jodie L, et al. Effects of moderate and substantial hypoxia on erythropoietin levels in rainbow trout kidney and spleen. J Exp Biol 2006; 209: 2734-8. Published by The Company of Biologists 2006.
44. Rojas DA, Perez-Munizaga DA, Centanin L, Antonelli M, Wappner P, Allende ML, et al. Cloning of hif-1alpha and hif-2alpha and mRNA expression pattern during development in zebrafish. Gene Expr Patterns 2007; 7(3): 339-45.
45. Bayliss P, Bellavance K, Whitehead G, Abrams J, Aegerter S, Robbins H, et al. Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol 2006; 2(5): 265-73.
46. Larson JD, Wadman SA, Chen E, Kerley L, Clark KJ, Eide M, et al. Expression of VE-cadherin in zebrafish embryos: A new tool to evaluate vascular development. Dev Dyn 2004; 231(1): 204-13.
47. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353(8): 782-92.
48. Takagi H, Watanabe D, Suzuma K, Kurimoto M, Suzuma I, Ohashi H, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2007.
49. Galeano M, Altavilla D, Cucinotta D, Russo GT, Calo' M, Bitto A, et al. Recombinant Human Erythropoietin Stimulates Angiogenesis and Wound Healing in the Genetically Diabetic Mouse. Diabetes 2004.
50. Alvarado S. Regeneration in the metazoans: Why Does it Happen? BioEssays 22,588, 2000
51. Leyland-Jones V, Semiglazov M, Pawlicki T, Pienkowski S, Tjulandin G, Manikhas, et al. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study, J Clin Oncol 2005; 23: 5960-72.
52. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo controlled trial, Lancet 2003; 362: 1255-60.
53. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-13.
54. Lai SY, Grandis JR, Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 2006; 24: 4675-6.
55. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression, Blood 2006; 107: 1892-5.
56. Danish Head and Neck Cancer Group, Interim analysis of DAHANCA 10, 2006, 12, 1, Available at http://frejacms.au.dk/dahanca/ get_media_file.php?mediaid=125. Accessed May 12, 2007.
57. U.S. Food and Drug Administration, http://www.fda.gov/medwatch/ safety/2007/safety07.htm #Aranesp, Accessed May 12, 2007.
58. Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007; 50(5): 591-6.
59. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007; 50(5): 636-4.
60. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007; 2: E549.
61. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354(19): 2079-80.
62. Agency for Healthcare Research and Quality. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. May 2006. Available at http://effectivehealthcare.ahrq.gov/. Accessed May 23, 2006.
63. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505.
64. Sanchez Alvarado A. La règènèration tissulaire, Biofutur, 213,48,juillet 2001
65. Quesenberry PJ, Colvin GA, Lambert JF. The chiaroscuro stem cell: A unified stem cell theory. Blood 2002; 100: 4266-71 - Lambert JF, Liu M, Colvin GA. Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit. J Exp Med 2003; 197: 1563-72.
66. Al-Wqati Q, Oliver JA. Stem cells in the Kidney Kidney Int 2002; 61: 387-95
67. Ding S, Wu TY, Brinker A. Synthertic small molecules that control stem cell fate. PNAS 2003; 100: 7632-37 - He JQ, MA Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ Res 2003; 93: 32-9.
68. Owen M, Friedenstein A. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 1988; 136: 42-60.
69. Colter DC, Class R, Di Girolamo CM. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. PNAS 2000; 97: 3212-18.
70. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transitino durino tumor progression. Curr Opin Cell Biol 2005; 17: 548-58.
71. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2006; 7: 131-42.
72. Zeisberg M, Shaa AA, Kalluri R. Bone morphohenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 2005; 280: 8094-100.